BioSpace News Archive

Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. for the development of dotinurad to include the Middle East and North Africa and Turkey territories.

invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.

Nexcella, Inc. announced that it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial as of June 27, 2022 data cutoff with a median of 6 prior lines of therapy.

TRACON Pharmaceuticals (NASDAQ: TCON) today announced the IDMC for the ongoing ENVASARC Phase 2 pivotal trial recommended continued accrual as planned in both cohorts: single agent envafolimab and envafolimab in combination with Yervoy (ipilimumab).

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced the receipt of a follow-on production order totaling approximately $2.6 million from a major US defense contractor, to meet increased demand for a highly complex optical assembly.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the results of a study in which enumeration and genomic characterization of CTCs at varying stages of MM represents an invaluable tool to predict disease aggressiveness and pathology.

Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, announced the live deployment by the University of Pittsburgh Medical Center of Galen™ Prostate, an AI-based solution that supports pathologists during cancer diagnosis, at the UPMC network.

Myrtelle Inc., (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug (OD) designation for rAAV-Olig001-ASPA, the company’s lead gene therapy product candidate for the treatment of Canavan disease.

Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in non-small cell lung cancer (NSCLC), the second indication being studied in the company’s national PREDAPT study that will ultimately encompass 11 cancers.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced it will host a virtual investor Business Briefing with Q&A on December 20, 2022, at 10:30 am ET.